Literature DB >> 1802535

Quality control limits for disk diffusion and broth microdilution susceptibility tests with Haemophilus test medium.

G V Doern1, E H Gerlach, J H Jorgensen, P R Murray, C Thornsberry, J A Washington.   

Abstract

A six-center collaborative study was performed with the aim of developing quality control test limits for both disk diffusion and broth microdilution susceptibility tests with Haemophilus influenzae ATCC 49247 using Haemophilus test medium. Quality control ranges are presented for 18 antimicrobials: ampicillin, amoxicillin-clavulanate, ampicillin-sulbactam, cefuroxime, cefamandole, cefonicid, cefotaxime, ceftriaxone, ceftizoxime, ceftazidime, cefixime, chloramphenicol, tetracycline, trimethoprim-sulfamethoxazole, rifampin, imipenem, aztreonam, and ciprofloxacin.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1802535     DOI： 10.1016/0732-8893(91)90004-y

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  12 in total

Review 1.  In vitro susceptibility testing of Haemophilus influenzae: review of new National Committee for Clinical Laboratory Standards recommendations.

Authors:  G V Doern
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycin.

Authors:  M J Bale; R N Jones; M E Erwin; F P Koontz; E H Gerlach; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

3.  Cervical necrotizing fasciitis in an infant caused by Haemophilus non influenzae.

Authors:  A M Cordeiro; A Bousso; I de Cassia; O F Fernandes; J C Fernandes; F M Elias; W A Jorge; B Ejzenberg; Y Okay
Journal:  Infection       Date:  1997 Nov-Dec       Impact factor: 3.553

4.  Comparison of agar dilution, broth dilution, and disk diffusion testing of ampicillin against Haemophilus species by using in-house and commercially prepared media.

Authors:  P C Kohner; J E Rosenblatt; F R Cockerill
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

5.  Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains.

Authors:  Federico Román; Rafael Cantón; María Pérez-Vázquez; Fernando Baquero; José Campos
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

6.  Quality control guidelines for cefdinir, cefepime, cefetamet, cefmetazole, cefpodoxime, cefprozil, and clinafloxacin (CI-960) for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Quality Control Study Group.

Authors:  M J Bale; R N Jones
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

7.  Variation in the composition and pore function of major outer membrane pore protein P2 of Haemophilus influenzae from cystic fibrosis patients.

Authors:  A G Regelink; D Dahan; L V Möller; J W Coulton; P Eijk; P Van Ulsen; J Dankert; L Van Alphen
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

8.  Development of revised quality control limits for disk diffusion susceptibility tests of selected cephem antibiotics with Haemophilus influenzae and description of a new control strain.

Authors:  J H Jorgensen; A L Barry; G V Doern; M J Ferraro; P R Murray
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

9.  Haemophilus influenzae ATCC 49766, an alternative quality control strain for monitoring broth microdilution susceptibility tests with selected beta-lactams.

Authors:  A L Barry; J H Jorgensen; D J Hardy; S D Allen; C N Baker
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

10.  Revised disk diffusion interpretive criteria for cefaclor, loracarbef, cefprozil and cefixime when testing Haemophilus influenzae on haemophilus test medium.

Authors:  G V Doern; R N Jones; E H Gerlach; J Hindler; R St Amand
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-06       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.